New York, Jan 25, 2026, 05:38 EST — Market closed
- Shares of ImmunityBio dropped 12.1% on Friday following a turbulent trading session
- Company highlighted new data from a recurrent glioblastoma study, set to be presented on Jan. 31
- Traders are now focused on details about durability, safety, and upcoming trial phases
ImmunityBio, Inc. (IBRX) shares closed Friday down 12.1% at $6.45, having traded as high as $7.88 and as low as $6.43 amid heavy volume. 1
This move is significant since the stock’s been riding momentum, but Friday’s pullback hands control back to next week’s data releases. Monday’s open will reveal if dip buyers return or decide to sit it out.
On Friday, the company highlighted new Phase 2 data from its QUILT-3.078 trial targeting recurrent or progressive glioblastoma, a tough-to-treat brain cancer. ImmunityBio reported that median overall survival was “not yet reached” as of Jan. 22, with 19 out of 23 patients still alive. The updated results are set to be shared on Jan. 31. 2
Simon Khagi, medical director of neuro-oncology at the Hoag Family Cancer Institute and a trial investigator, noted that median overall survival for recurrent glioblastoma typically falls between “approximately 6 to 9 months” in recent studies. He described the chemotherapy-free regimen’s durability and safety as “a paradigm change.” 3
Put simply, “median not reached” means over half the patients were still alive when they ran the analysis. The company also pointed to reversal of lymphopenia — abnormally low lymphocyte counts — and described CAR-NK as engineered natural killer cells designed to enhance the immune response. 4
The regimen features Roche’s Avastin (bevacizumab), already approved for glioblastoma in adults with cancer that has advanced after earlier therapies—a detail likely to influence investor views on the trial’s design and selection of comparators. 5
The treatment also incorporates Tumor Treating Fields, a device method most recognized from Novocure’s offerings. These devices emit low-intensity electric fields and have already gained approval for glioblastoma. 6
But the data is preliminary. QUILT-3.078 features an open-label, single-arm Phase 2 segment alongside a randomized arm, where small sample sizes can skew results—amplifying both positive and negative signals. This kind of design often sparks volatile moves in the stock. 7
Friday’s overall market showed caution, with major indexes ending mostly flat. That offered little boost to risk appetite, especially for smaller biotech stocks. 8
After the Jan. 31 presentation, investors are already looking ahead to ImmunityBio’s next financial update, expected in early March according to market calendars. 9
